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Abstract
Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach
Lewei (Allison) Lin, (Sponsored by: Robert Rosenheck), Department of Psychiatry, Yale
University School of Medicine, New Haven, CT

HYPOTHESIS/AIMS: Apply health state analysis to a large clinical trial dataset of
patients with schizophrenia to provide added insights into clinical and quality of life
characteristics. We also evaluated the hypothesis that there is no difference in the distribution of
health states of patients across several antipsychotic medications. METHODS: This study was a
secondary analysis of data from the CATIE trial, a multi-site double blind clinical trial of
antipsychotic treatments for schizophrenia. We applied K-means clustering to the CATIE data,
creating discrete clusters with symptom and side effect characteristics that were then validated
using a panel of quality of life measures. A comparison was made across medications for
differences in cluster distributions at baseline and 6 months. RESULTS: 1049 patients from the
CATIE trial dataset were included for initial cluster analysis. By examining cluster profile plots,
it was determined that 5 was the optimum number of health states. Using intent to treat, the model
was applied to compare 6-month outcomes for patients on perphenazine, olanzapine, risperidone
and quetiapine. Chi square tests of independence showed significant difference (p=0.0090) in the
distribution of patients across health states for the 4 medications at 6 months. Chi squared
pairwise comparisons were significant for only perphenazine vs. risperidone (p = 0.012 < α of
0.025 with Hochberg correction) and for olanzapine vs. risperidone (p= 0.0010 < α of 0.05) but
not for any other pairs. At baseline, almost 20% of patients were in the worst health state
(HS+Dp+Ak), but decreased at 6 months, with the greatest decreases in the pherphenazine (9.2%
decrease) and olanzapine (11.1%) groups compared to risperidone (4.7%) and quetiapine (6.7%).
There was a large increase in the best health state (LS+LSE) for patients taking perphenazine
(15.0%), olanzapine (18.5%) and quetiapine (12.0%) but less for patients taking risperidone
(4.5%). CONCLUSION: This study demonstrated health state analysis is a useful tool that
provides information on the overall clinical state of patients and can potentially be used to help
guide clinicians in treatment decisions.
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Introduction

Comparative effectiveness research today
With the advent of many new treatments for psychiatric illnesses in the last fifty
years, there has also been greater uncertainty about the relative effectiveness amongst
treatments and the impact on a patient’s overall well-being. Comparative effectiveness
research is potentially a powerful approach to improve quality of care and outcomes.
With the passing of the American Recovery and Reinvestment Act of 2009, policy
makers not only acknowledged its importance, but also allocated $1.1 billion to support
new research and to create the Federal Coordinating Council for Comparative
Effectiveness Research, an organization to oversee its development (1).

In 2007, the Institute of Medicine defined comparative effectiveness as the
“comparison of one diagnostic or treatment option to one or more others” and others have
defined it as the study of risks and harms associated with alternative options of health
care and their impact on patients (2) (1). Comparative effectiveness studies have been a
recent focus of research trials because of their potential to improve clinical care.
However, the IOM has estimated that only half of the treatments that are considered
standard of care have shown to be clinically effective in research trials and that the
degree to which one treatment is more effective than another is in most cases unclear due
to the lack of evidence (3). The roots of this problem may lie deep in the US healthcare
system. For example, the Food and Drug Administration requires evidence on the safety
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profile and effectiveness of new treatments as compared to placebo but does not typically
require comparisons to be made with previously approved alternatives. There is
increasing clinical research comparing treatments but it is still recognized that there is not
enough comparative research that can be directly clinically relevant (4).

A need for CEA studies of antipsychotics
Comparative effectiveness research may be particularly important in evaluating
treatments for schizophrenia. Since the discovery of chlorpromazine in the late 1950’s,
there has been an explosion of new antipsychotic medications on the market. In 2007,
there were over sixty approved antipsychotics worldwide (5). These medications are
usually divided into two categories, first generation antipsychotics, including
chlorpromazine, were those discovered prior to clozapine. In the 1980’s, reports were
published about clozapine indicating unprecedented efficacy in treating refractory
schizophrenia (6). All drugs discovered after its release was marketed as a new and
distinctly superior category with fewer extrapyramidal symptoms and were labeled
atypical or second generation antipsychotics (SGA’s).

Initially it was thought that the SGA’s would be at least as effective in treating the
positive symptoms of schizophrenia (hallucinations, delusional thinking, and thought
disorganization), but would result in fewer side effects. In addition, SGA’s were thought
to be promising for treating negative symptoms (anhedonia, flat affect, paucity of speech)
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cognitive impairments and mood symptoms. Based on these hopes, large professional
bodies around the world including the American Psychiatric Association, the World
Psychiatric Association, the United Kingdom’s National Institute for Health and Clinical
Excellence, and the Texas Medication Algorithm Project recommended the newer
medications in favor of the old (7) (8) (9) (10). Some thought the SGA’s would render
FGA’s obsolete (11).

Subsequently, use of SGA’s have soared along with costs. In 1994, the annual
expenditures on antipsychotic medications in the U.S. was $1.4 billion and less than 5%
of schizophrenic patients received SGA’s (12). Ten years later, 90% of patients received
SGA’s and the annual expenditure totaled over $10 billion, with 70% paid by the U.S
government through Medicaid (12). A similar story unfolded globally. Global
expenditures on antipsychotic medications increased from $0.5 billion annually in the
1990’s to more than $15 billion annually a decade later (13). This increase was driven by
use of SGA’s which cost 5-30 times more than FGAs. Such costs could be justified if
patients experienced significant symptom reduction and overall improvement in quality
of life, but there is increasing skepticism about overall benefit. Such uncertainty has led
to a growing literature of systematic reviews and large scale clinical trials comparing
effectiveness of antipsychotic medications.

One of the first comprehensive systematic reviews was published by Geddes et al.
in 2000 (14). That analysis included results of 52 randomized trials published before
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Dec. 1998 comparing SGA’s (amisulpride, clozapine, olanzapine, quetiapine, risperidone,
and sertindole) with FGA’s (most commonly haloperidol or chlorpromazine). Outcome
measures included symptom measures and side effects. The study concluded that SGA’s
were equally effective as a group and were no more effective than FGA’s when they
controlled for higher than recommended doses of FGA’s in trials. SGA’s still showed a
moderate benefit in EPS symptoms, but there were no significant difference in dropout
rates.

In contrast, a review published by Davis et al in 2003 concluded that SGAs were
not a homogenous group in terms of effectiveness. That analysis included 142
randomized controlled trials (published and unpublished data) up to May 2002 comparing
ten SGA’s with FGA’s in patients with schizophrenia or schizoaffective disorder (15).
The main outcome measure was symptom scores. The study concluded that four SGA’s
(clozapine, amisulpride, risperidone, and olanzapine) were significantly more effective
than FGA’s. The remaining SGA’s (aripiprazole, quetiapine, remoxipride, sertindole, and
ziprasidone) were no more effective than FGA’s. And unlike the Geddes et al. study,
they found no evidence that the dose of FGAs affected the results.

Leucht and colleagues published the most recent review in 2009 comparing nine
SGA’s with FGA’s on a variety of outcome measures, including symptoms, relapse rates,
quality of life, EPS, weight gain and sedation (16). Their review included 150 doubled
blind studies published before Aug 2005. They concluded that the same 4 SGAs
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highlighted in the Davis et al review (amisulpride, olanzapine, clozapine, and
risperidone) were significantly more effective in treating both positive and negative
symptoms with small to medium effect sizes and that aripiprazole, quetiapine, sertindole,
ziprasidone, and zotepine were no more effective than FGA’s. In addition, SGA’s
resulted in fewer EPS symptoms compared to haloperidol even at low doses, but the
difference in EPS compared with less potent FGA’s was less clear. However, SGA’s
(except for aripiprazole and ziprasidone) were associated with greater weight gain. They
also concluded that few studies included data on quality of life and relapse rates. Leucht
and colleagues also compared the results of their review with the others reported here as
well as the Cochrane Reviews and concluded that all of the reviews demonstrated that
amisulpride, clozapine, olanzapine and risperidone were superior to FGAs but for the
other SGAs, there were no significant differences (17) (16).

The need for more objective and definitive evidence comparing effectiveness of
different antipsychotics on the market also led to two large scale government sponsored
multi-site trials on the long term effectiveness of medications to treat schizophrenia. The
Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
from the United Kingdom was a large (N=227) randomized clinical trial with a study
design that mimicked real world prescribing practice. Clinicians were allowed to
prescribe any SGA (excluding clozapine in the first arm of the study) and any FGA
medication and both patients and clinicians were not blind to treatment assignment. This
design resulted in a high 12 month followup rate of 81%, but found SGAs showed no
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significant advantage over FGAs after one year on measures of quality of life, symptoms,
discontinuation, or side effects.

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for
schizophrenia was sponsored by the National Institute of Mental Health and conducted
between 2001 and 2004. 1460 patients were followed for up to 18 months at 57 sites in
the U.S and clinicians and patients were blinded to treatment assignment (18). CATIE
compared the effectiveness of one first generation antipsychotic, perphenazine, with the
four second generation antipsychotics available on the market at the time. Primary
CATIE results found olanzapine to be associated with significantly longer time to
discontinuation compared to quetiapine and risperidone but the difference was not
significant in the perphenazine comparison. Time to all cause treatment discontinuation
was significantly longer for clozapine in a treatment resisitant arm of the study compared
to quetiapine and risperidone but not to olanzapine. And the overall discontinuation rate
was high – 74% of patients discontinued their study medication before the end of trial at
18 months. There were no significant advantages of second generation antipsychotics
over perphenazine on symptoms, neurologic side effects, quality of life, employment, or
neurophsychological functioning (19). Perphenazine was less costly by $300-500 per
month compared to all SGA’s when accounting for medication costs and costs of health
services utilized (20).
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These reviews and clinical trials have been some of the largest to date, but they
have not been without criticism. More than 80% of the studies included in Leucht et al.’s
meta analysis had a study period of 12 weeks or less, even though long term treatment of
schizophrenic patients is needed to prevent relapse. Moreover, most of the trials included
in the analysis are from early drug studies sponsored by pharmaceutical companies,
which can skew the evidence in favor of those drugs over comparisons (21). In addition
the choice of comparison drugs in 95 out of 150 of Leucht’s analysis was haloperidol, a
high potency FGA. Few studies chose medium potency drugs, such as perphenazine,
which is thought to be associated with lower rates of EPS (22).

Although it was hoped that results from these two large scale studies would
provide conclusive answers, the results actually fueled more debate. On one side, led by
the primary investigators of the studies, the results were interpreted to suggest that SGA’s
confer no additional clinical benefit over FGA’s. On the other side, the argument is that
the study methodologies were flawed and caution should be used in applying the results.
Critics of the CATIE study point to several components. In particular, they question the
results indicating no difference in tardive dyskinesia (TD) across the medications. In the
CATIE trial, patients with tardive dyskinesia (about 15% of the sample) were excluded
from being randomly assigned to perphenazine because it was generally thought in 2000
by an expert panel that patients with TD should not be exposed to any FGA (23). Critics
say this exclusion may have biased the samples so that those assigned to perphenazine
were not as severely ill as those assigned to other medications. However the study
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investigators have pointed out that this issue was already addressed in the study design
and analysis. In the analysis, perphenazine patients were only compared to equivalent
patients who did not have tardive dyskinesia at baseline.

Although there were some differences between the results of CATIE and
CUtLASS and those of the meta analyses, overall, the evidence suggests that FGA’s and
SGA’s are not homogenous groups of medications and that each drug should be judged
on its own efficacy and risk of side effects. Furthermore, with the results of such large
scale multi-site government sponsored studies, there is also enough evidence to suggest
that SGA’s as a group are no more effective than FGA’s, even though the debate will still
likely continue. And as more is learned about the mechanisms of SGA’s, it is apparent
that the mechanisms of drugs in this category differ significantly from one another. For
example, it was thought that the property of blocking serotonin receptors accounts for
their improved efficacy, but many of the most potent serotonin blockers are not more
efficacious and amisulpride, which is not a serotonin blocker, is more effective than
many other SGA’s (15).

Yet, as some recent studies have shown, the knowledge gained from these large
scale, carefully designed trials is not being disseminated widely to clinicians and is not
having widespread impact on prescribing practices. A European survey of psychiatric
trainees show that 96% of trainees prefer “atypical” antipsychotics for the acute treatment
of schizophrenia and cite efficacy as the primary (76%) factor for their prescription
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choices (24). Side effect profile (21%) and cost (3%) played less of a role. Thus, it is still
the case that many clinicians reach first for SGA’s for schizophrenia under the
assumption that the drugs are more effective and have reduced side effects
How can CEA be more useful to clinical care?
One barrier in disseminating information from comparative effectiveness studies
may be that the results are not always directly applicable to treatment selection for a
specific patient with a complex clinical profile. Clinical trials often incorporate methods
such as subgroup analysis to look for effects that may pertain to specific patient
populations, but such analysis is often not comprehensive and there are statistical
challenges in their interpretation (1). However, even the most well designed clinical trials
often fail to provide conclusions that can guide the crucial question of “what is the best
treatment for this particular patient?”

Outcomes of trials are usually reported using dimensional scales and comparisons
are made using averages along dimensions of health including symptoms, side effects,
and overall quality of life. This approach cannot capture important and complex
relationships between different dimensions of health (25). And in clinical practice,
treaters must routinely assess the relative benefit of symptoms and side effects as they
emerge in multidimensional health states. Comparative effectiveness research has been
urged to develop methods to provide insight into overall clinical impact of medications
because an individual patient can experience both benefit and harm from a given
treatment (26).

14

Need for new methods – health state analysis as an alternative approach

Health state modeling is an analytic method that could potentially improve the
practical value of comparative effectiveness research. In this data driven approach,
cluster analysis is used to classify patients. Cluster analysis is a way of dividing data into
meaningful or useful groups by capturing the natural structure of the data. This technique
is widely used in many fields including psychology, biology, statistics, pattern
recognition, machine learning and data mining (27).

Measurements at particular points in time can then be grouped into discrete multidimensional health states such that patients in a given state are as similar as possible over
several dimensions of symptoms and side effects. Clinically relevant change can then be
measured as the probability of moving individuals from one health state to another rather
than the traditional approach of measuring net increase or decrease over time on multiple
preset scales. One can then compare randomized treatments by the differing probabilities
of causing desirable transitions. For example, patients in two treatment groups can have
similar levels of overall health, but one treatment increase the likelihood that patients
have severe symptoms and few side effects while the other group leads to severe side
effects but few symptoms. Health state modeling could clearly distinguish between these
two types of outcomes.
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Health state modeling has the additional benefit of providing a simple way to
estimate long run outcomes using data from studies of a finite duration using Markov
chain theory. The transition probability from one health state to another can be
accumulated over several time periods and across the entire patient sample to determine
the distribution of patients in each health state at equilibrium with different treatments
(28). These long run health states can be used to estimate health related utility levels or
Quality Adjusted Life Years for use in cost-effectiveness or cost benefit analysis (29).

This method has recently been used to compare outcomes of patient populations
from different mental health programs in a paper by James et al (30). In this study, they
compare the health state modeling approach to a conventional mixed effects regression
model in the analysis of longitudinal data of patients treated at a Veterans Affairs (VA)
medical center versus patients treated at a Community Mental Health Center (CMHC).
Although both methods produced similar conclusions – patients treated at the CMHC
were more stable over time compared to VA treated patients, the health state analysis
gave additional insight into which subgroups of the VA population were developing more
severe symptoms. The analysis showed that patients in the best and worst health states
changed little over time, but patients with mild symptoms with hallucinations and
patients with severe positive and negative symptoms were the most likely to deteriorate.

In another recent clinical trial, health state analysis was used to compare
effectiveness and cost effectiveness of haloperidol and clozapine (25). A secondary
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analysis was conducted of a randomized controlled trial comparing haloperidol and
clozpaine in a hospitalized VA patient population. The health state model consisted of
clusters with different symptom and side effect profiles. The study concluded that
clozapine, compared to haloperidol, differentially increased the proportion of patients
with mild symptoms and decreased the proportion of patients with severe positive
symptoms, but the proportion of patients with negative symptoms stayed relatively
constant over time. And projecting long run outcomes and health costs using a Markov
model, the study authors conclude that clozapine is more cost effective compared to
haloperidol.

In this study, we apply health state modeling as a secondary analysis of data from
the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia
trial. We use the primary data from this large study, which tried to represent a real world
cohort of patients through its broad inclusion and exclusion criteria. Although the original
analyses have provided insight into treatment effects on specific dimensions of health, the
overall impact of medications remains ambiguous. In this study, we re-analyze the data
from CATIE using a health state approach.

Statement of aims and hypotheses

Aim 1
Determine if health state analysis can potentially provide a richer picture of the clinical
and quality of life characteristics of this patient population.
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Hypothesis 1
Health state analysis results in additional insights into the clinical and quality of life
characteristics of patients compared to traditional dimensional approaches.
Aim 2
Apply health state analysis to compare the impact of various common antipsychotic
medications on the health state outcomes of patients.
Hypothesis 2
There is no difference in the distribution of health states of patients across medications
over the treatment time period.

Methods

Study design
CATIE was conducted between January 2001 and December 2004 at 56 U.S.
sites. The study was designed to compare effectiveness and cost-effectiveness of one first
generation antipsychotic, perphenazine and the second generation antipsychotics
olanzapine, quietiapine, risperidone and ziprasidone. Details of the study and exclusion
criteria have been reported elsewhere (31) (32). An algorithm assigned patients to a series
of treatment phases. In phase 1, patient were assigned to medications under double-blind
conditions and were followed up to 18 months or until treatment was discontinued for
any reason. Patients with tardive dyskinesia (15% of the sample) were excluded from the
randomization that included perphenazine, and these patients with a history of TD
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baseline were excluded from our analyses. Patients who discontinued the first medication
they were assigned were invited to start another second-generation antipsychotic and
open treatment was offered to patients who refused the second random assignment or
who failed the second randomization. In the present analysis, we used a subset of data on
patients treated with perphenazine, olanzapine, quetiapine and risperidone because
ziprasidone was introduced after much of the sample had been recruited.
Measures
The data consisted of symptom measuring instruments including the Positive and
Negative Syndrome Scale (33). The PANSS has 3 subsections: positive symptoms such
as hallucinations and delusions, negative symptoms such as blunted affect, and general
emotional disturbance such as anxiety and depression. The Calgary Depression Symptom
Scale for Schizophrenia (34) further assesses specific neurovegatative and subjective
aspects of depression including sleep, suicidality, and hopelessness. In this analysis, we
used summed scores from the subsections of the PANSS and the total Calgary score.
Extrapyramidal side effects were assessed using the Abnormal Involuntary Movement
Scale (35), the Barnes Akithesia Scale (36)and the Simpson-Angus Scale (37). The BMI
was also included as a measure of metabolic side effects. With the exception of BMI, all
of these instruments use Likert scales to measure symptom severity with higher scores
indicating more severe symptoms.

A broad selection of quality of life measures were used as validation measures for
overall severity and impact of illness associated with each health state. These were
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assessed as part of the original CATIE study and in this analysis, also serve as a measure
of relative illness severity and psychosocial functioning associated with patients in each
cluster. The measures include the Lehman Quality of Life summary item (38), a semistructured interview that assesses the overall life circumstances of patients with mental
illness. The SF12 mental and physical subscales (39) are summary scores from a patient
administered health related quality of life survey that has been widely used in many
patient populations. The Heinrichs Carpenter Quality of Life Interview (40) was
originally developed to assess the schizophrenia deficit syndrome and contains subscales
measuring interpersonal relations, occupation, intrapsychic foundations (motivation,
anhedonia, emotional interaction) and common objects and activities. Finally, the Visual
Analogue Scale is a patient’s self reported measure of overall health. Data were collected
at baseline, 1, 3, 6, 9, 12, 15, and 18 months.

Analyses
We use K-means clustering on the standardized symptom and side effects
measures to obtain discrete health states. K-means is a partitioning algorithm that treats
each observation in the dataset as an object with a location in multi-dimensional space
defined by the characteristics that are measured (28). The algorithm creates clusters of
observations, where each cluster is defined by the patient members that have been
assigned to it and by its centroid, or the center point of all the members in that cluster. Kmeans is an iterative algorithm that minimizes the sum of distances from each member in
the cluster to its cluster centroid and over all clusters. The process involves moving
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objects between clusters until the sum of distances has reached a global minimum. This
results in non-empty non-overlapping clusters where members in each cluster are as close
together as possible and where members in different clusters are as far apart as possible.

The most important technical issue to consider in k-means cluster analysis is the
selection of k, the number of clusters used. K is a user defined value that can take on any
integer value. It is important to have as few clusters as possible for ease in interpreting
results and to allow for enough subjects in each cluster for adequate statistical power.
However, it is also important to have enough clusters so that patients who appear
clinically different are not grouped into the same cluster. In this study, we use cluster
profile plots as a visual tool to aid in selection of clusters. For each cluster, we plot the
average score for each outcome score across all patients who belong to that cluster. We
produce plots for different values of k and compare the patterns of plots to choose the
greatest value of k where each cluster plot appears clinically distinct. We increase k as
long as addition of clusters results in separation of cluster centers along at least one of the
clinical axes. This plot provides a picture of the average patient in each cluster and can
also be used to provide a narrative description of these patients for purposes of utility
measurement. In addition, we use quality of life measures as a way of validating and
differentiating the severity of the health states.

After choosing the number of clusters and removing patients with missing values,
we ran the k-means cluster algorithm on the symptom and side effect data to produce the
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health state model. We then used the health state model to compare outcomes across
medications over time. Specifically, we compared the proportion of patients in each
health state at baseline and then at time 6 months across medications. We examined the
data cross-sectionally using chi-square tests of independence to determine if there were
significant differences of health state patterns across the treatment groups at each time
point.

Next, we looked at long run differences in patterns of health states across
medications. Before applying Markov chain theory, we tested assumptions of stationarity
of the data, to determine whether the transition probabilities from one state to another
remain fixed over time. With data that remains stationary, one can calculate a stationary
distribution, which is the fraction of patients residing in each health state modeled after
many time periods.

In this study, the initial clustering was performed by Dr. Catherine Sugar, a
professor of biostatistics at UCLA who helped develop the health state technique. The
planning for the cluster analysis and selection of the optimum number of clusters were
done in partnership with her and all data interpretation was performed by this paper’s
author.
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Results

Sample Characteristics
Appendix 1 depicts the demographic and clinical characteristics of patients at the
time of initial random assignment in this study. The average age is 39.3. 74% of patients
are male. 60.1% of patients are White and 60.6% of patients have never been married.
The average burden of psychotic symptoms as measured by the PANSS total is 75.5.
Patients on average are overweight, bordering on obese with BMI of 29.8. The average
monthly cost of all healthcare received is $2,299.

Generating clusters
In order to determine the optimal number of health states, all available
observations with complete information on outcomes measures across all time points
were used. By examining cross-tabulation tables and cluster profile plots using different
number of clusters, it was determined that 5 clusters allowed for the greatest amount of
differentiation amongst clinically meaningful clusters with the most parsimonious and
interpretable set of clusters. Fig. 1 shows the cross-tabulation of cluster memberships
between 4 and 5 cluster models. In the figure, the rows represent the 4 cluster model and
columns represent the 5 cluster model. So the value in the first row, second column
shows the number of people who were in cluster 1 in the 4 cluster model and cluster 2 in
the 5 cluster model. The numbering of clusters is arbitrary in this case – for example, the
majority of patients in cluster 2 in the 4 cluster model are in cluster 3 in the 5 cluster
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model. But patients in cluster 4 become distributed in clusters 4 and 5 in the 5 cluster
model. This indicates that most patients stay assigned to the same cluster, but that most
of the patients in cluster 4 become reassigned to form clusters 4 and 5 in the 5 cluster
model.

Figure 1. Cross tabulation of 4 cluster and 5 cluster models. Values represent number of
patients in each cluster under 4 cluster (rows) and 5 cluster (columns) models.

1
2
3
4
Column
Total

1
196
39
3
1

2
92
35
13
1

3
0
350
55
2

4
0
3
172
36

5
0
0
0
36

239

141

407

211

36

Row
Total
288
427
243
76
1034

We examine cluster profile plots in order to determine the clinical differences
between these clusters. Figure 2 shows 4 plots corresponding to each cluster in the 4
cluster model. In each plot, the values shown are the re-centered scores calculated by
subtracting the global mean from each score. This allows one to compare values across
all outcome measures for which the raw scales scores are measured on different scales.
For example, cluster 1 is comprised of patients with low symptoms and low neurological
side effects but high BMI scores. In the 5 cluster model, shown in Fig. 3, patients in
cluster 1 have low symptoms, neurological side effects and low BMI scores, while cluster
2 is a distinctly new cluster with low symptoms and side effects but strikingly high BMI.
The BMI in cluster 2 is over 10 points higher than all other clusters. Thus, the 4 cluster
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model has too few clusters to capture the clinical diversity in the patient sample. The
addition of clusters beyond 5 produced some additional distinctions in specific movement
side effects, but the additional clusters come at the cost of interpretability, parsimony, and
power for long run Markov analysis.

Figure 2. Cluster plots for 4 cluster model with re-centered scores on Y axis and question
number corresponding to specific questions on all 8 symptom and side effects scales on X
axis.
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Figure 3. Cluster plots for 5 cluster model with re-centered scores on Y axis and question
number corresponding to specific questions on all 8 symptom and side effects scales on X
axis.
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Objective descriptions of the health states were then created from the mean scores
of outcome measures of each health state and are shown in Table 1. For example, patients
in cluster 4 in the 5 cluster model had high scores on all sections of the PANSS, highest
depression scores, and high akithesia compared to other patients in the sample. In
summary, the health states can be characterized as: 1) low symptoms and low side effects
(LS+LSE) 2) low symptoms and obesity (LS+Ob) 3) high symptoms and low side effects
(HS+LSE) 4) high symptoms with depression and akithesia (HS+Dp+Ak), and 5)
moderate symptoms and high side effects (MS+HSE)

Table 1. Mean (std. dev.) of 8 outcome measures across 5 clusters
PANSS PANSS PANSS
Simpson
Cluster n
Pos.
Neg.
Gen.
Calgary AIMS Barnes Angus
BMI
1
2674
12.2
14.9
26.0
10.9
1.0
0.6
0.6 27.8
(3.6)
(4.7)
(5.2)
(2.5)
(2.1)
(1.5)
(1.1) (4.3)
2
1310
14.6
16.9
30.7
12.2
1.0
0.6
0.7 40.6
(4.2)
(4.6)
(6.2)
(3.3)
(2.1)
(1.4)
(1.2) (5.7)
3
2244
20.4
23.3
40.0
12.2
1.0
0.5
0.8 28.0
(5.0)
(5.4)
(6.9)
(3.1)
(2.2)
(1.1)
(1.2) (5.2)
4
1095
20.2
21.4
43.3
19.4
2.9
4.2
1.9 30.3
(5.0)
(5.8)
(8.0)
(4.5)
(3.9)
(2.9)
(2.1) (7.1)
5
852
16.8
20.0
35.6
12.0
10.5
2.8
3.8 29.2
(5.2)
(5.8)
(8.0)
(3.1)
(5.8)
(2.9)
(3.1) (5.8)

Concurrent Validation
In order to assess the differences in quality of life and overall psychosocial
functioning, we evaluated scores on 5 summary quality of life or social functioning
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measures and report the mean values for each cluster in Table 2. We use these scores as
an additional validation step in the choice of clusters. Patients in LS+LSE have highest
(least symptomatic) mean scores across all validation measures which is consistent with
the cluster characteristics of having the lowest symptoms and side effects. Patients in
cluster 4 (HS+Dp+Ak) have the lowest (worst) scores on all validation measures,
consistent with the high burden of symptoms and side effects in this group.

Table 2. Mean (std. dev.) of quality of life validation variables across 5 clusters
Clusters
1 LS+LSE

VAS¹ QOL31² HCTOT³ PCS12⁴ MCS12⁵
73.4
4.8
3.3
50.9
46.3
(21.2)
(1.2)
(1.1)
(8.5)
(10.2)
2 LS+Ob
68.2
4.6
3.0
46.7
43.5
(22.3)
(1.3)
(1.0)
(10.1)
(10.6)
3 HS+LSE
64.1
4.3
2.4
49.6
41.4
(25.4)
(1.3)
(1.0)
(9.3)
(11.1)
4 HS+Dp+Ak
47.1
3.6
2.3
45.0
32.1
(25.2)
(1.3)
(0.9)
(11.3)
(9.9)
5 MS+HSE
66.3
4.6
2.6
48.2
43.8
(24.0)
(1.3)
(1.0)
(9.6)
(10.1)
¹VAS: Visual Analog Scale (1-100)
²QOL31: Lehman Quality of Life (1-7)
³HCTOT: Heinrichs Carpenter Scale (0-6)
⁴PCS12: SF-12 physical health summary scale (0-100)
⁵MCS12: SF-12 mental health summary scale (0-100)

We used the 5 cluster health state model in a cross sectional analysis to compare
6-month outcomes across the four medications, perphenazine, olanzapine, risperidone
and quetiapine. We performed intent to treat analysis, but similar to the original CATIE
analysis, we excluded patients with a history of tardive dyskinesia at the baseline
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randomization from randomization to all of these drugs because those patients were
excluded from the perphenazine arm of the trial. Chi square tests of independence
between medication and health state at baseline showed no statistical difference (p =
0.19) at baseline across the medications. At 6 months, there was significant difference
(p=0.0090) in the distribution of patients across health states for the 4 medications.
Pairwise comparisons are performed between each pair of medications at 6 months (with
6 pairs in total). Chi squared test was significant only for perphenazine vs. risperidone (p
= 0.012 < α of 0.025 with Hochberg false discovery rate correction) and for olanzapine
vs. risperidone (p= 0.0010 < α of 0.05) but not for any other pairwise comparisons (41).

To assess specific differences in cluster distribution, we calculated the percent of
patients in each health state at baseline and then at 6 months, shown in Table 3. At
baseline, 19.7% of patients were in the worst health state, HS+Dp+Ak, and the health
state HS+LSE had the largest percentage of patients (over 38.9%). At 6 months, there
was an across the board decrease in patients in the worst health state (HS+Dp+Ak), with
the greatest decreases in the pherphenazine group (9.2% decrease) and olanzapine (11.1%
decrease) groups compared to risperidone (4.7% decrease) and quetiapine (6.7%
decrease) as seen in Table 4. There was a large increase in the best health state (LS+LSE)
for patients taking perphenazine (15.0%), olanzapine (18.5%) and quetiapine (12.0%) but
less for patients taking risperidone (4.5%). Patients in MS+HSE comprised the smallest
proportion of patients and this group also had the least evidence of change over the 6
months.
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Table 3. Percentage of patients in each cluster at baseline and 6 months

1
2
3
4
5

Clusters
LS+LSE
LS+Ob
HS+LSE
HS+Dp+Ak
MS+HSE

0
mths
24%
14%
39%
20%
4%

6
mths
36%
19%
27%
13%
6%

diff
12%
5%
-12%
-7%
2%

Table 4. Percentage of patients in each cluster at baseline and 6 months across
medications

1
2
3
4
5

perphenazine
0
6
mths mths diff
24% 39% 15%
15% 19%
4%
38% 29% -9%
17%
8% -9%
6%
6%
0%

0
mths
26%
10%
37%
24%
3%

olanzapine
6
mths diff
45%
19%
14%
4%
23% -14%
13% -11%
6%
3%

risperidone
0
6
mths mths diff
19% 24%
4%
15% 19%
4%
42% 35% -7%
21% 16% -5%
3%
6%
3%

0
mths
23%
14%
41%
19%
3%

quetiapine
6
mths diff
35%
12%
23%
9%
24% -17%
12%
-7%
6%
3%

Increases in the health state LS+Ob were similar across perphenazine (3.92%),
olanzapine (3.83%) and risperidone (4.40%) groups but were higher in the quetiapine
group (9.19%). Within the LS+Ob group, the average BMI of the olanzapine group
increased by 2.23%, while the BMI of all other medication groups decreased. Since
olanzapine was associated with greater weight gain in the original analysis (31), we
further examined continuous measures of BMI and found the difference in BMI from 6
months to baseline was largest for those patients taking olanzapine (mean 1.46, std dev.
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2.64) and smallest for perphenazine (mean -0.077, std. dev. 2.35). Thus changes in
obesity were not well captured by our clusters.

In this analysis, 34% of patients were re-randomized into a different arm of the
study or dropped out before 6 months. We compared the characteristics patients who
stayed on the original medication at 6 months and those who did not. There was no
significant difference on any characteristic and a MANOVA performed on the 5 quality
of life variables was not significant between the two groups (p = 0.52). Further analysis
of the phase 1 only sample (excluding observations after discontinuation of the initially
assigned drug) showed that Chi square comparisons across the 4 medications and
between any medication and perphenazine was not significant (p = 0.19 across all 4
medications). Likewise, Chi square comparison at 6 months was not significant across
all medications (p = 0.11). Comparisons between pairs of medications indicate only
olanzapine vs. risperidone was significant (p = 0.043 < α of 0.05 with Hochberg
correction). As expected, when examining only the phase 1 sample, there was a greater
increase in the best health state (LS+LSE, 15.9%) and greater decrease in the worst health
state (HS+Dp+Ak, 9.7%). The change in the LS+Ob cluster remains very similar 5.1%
compared to 5.0% in the entire sample.

Discussion

The goal of this study was to determine if the application of health state analysis
to data from a large clinical trial could provide additional insights into the overall impact
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of a set of widely used pharmacological treatments. To this end, we demonstrated that
health state approach can provide a richer picture of the overall clinical status of patients
than simple linear measures and can document transitions between states that can be
followed over time and compared between treatments. This approach could potentially
help researchers better communicate their findings to clinicians. It may also provide a
better description to patients of their expected symptom and side effect profiles if they
choose to remain adherent to a given treatment. We have also shown how health state
analysis can be used to account for overall changes in quality of life.

This is the first comparative effectiveness study, to our knowledge, that applies
health state analysis to clinical trial data of several commonly used antipsychotic
medications for the treatment of schizophrenia and is one of a small group of studies
employing health state analysis in general. Although the results of our study generally
confirm the results of original CATIE analyses that employed traditional methods to
compare outcomes using linear dimensions of health, this study provides additional
support for the view that second generation antipsychotic medications provide no
additional benefit over the first generation antipsychotic used in this trial.

An initial aim of this study was to determine if health state analysis could be
applied to data from a large clinical trial to identify simple and clinically meaningful
representations of a complex patient population with schizophrenia. To this end, we
created a model with 5 distinct health states that encompassed data from 4 categories of
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symptom measures and 4 side effect measures. Assuming 8 total dimensions of health
with a minimum of 3 levels in each dimension, a traditional full factorial design
describing the same population would have required at least 24 health states, even though
many of those states may not be occupied. Such large number of states would have
required a much larger sample of patients in order to obtain meaningful results.

With health state analysis, the selection of clusters is purely data driven by an
algorithm that minimizes within group differences and maximizes between group
differences. However, one can easily judge if the individual health states are distinctly
clinically meaningful. In this analysis, the 5 cluster model created health states with
average values on the symptom and side effect scales that could be easily described with
distinct clinical characteristics. Although, the description of health states using this
method introduces a level of clinically informed judgment, the benefit of having such a
parsimonious model allowing further analysis outweighs it. Furthermore, we conducted
additional validation analyses using a panel of commonly used quality of life measures.
We show that the LS+LSE health state is associated with the highest scores and highest
quality of life, which is intuitive clinically. Furthermore, the HS+Dp+Ak health state is
associated with the lowest scores on all four validation scales, with lower scores than
other health states (MS+HSE) which also have high symptom and side effect burdens.
The other three health states have varying scores on the different validation measures
depending on the associated attributes. For example, the LS+obesity health state has
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relatively low scores on the physical component of the SF12 quality of life instrument,
but a comparable score to MS+HSE on the QOL31, an overall measure of quality of life.

The next aim of our study was to determine if health state analysis could
potentially provide more information than traditional dimensional comparisons. In
studies using these traditional methods, outcomes are usually reported as average changes
on an outcome measure along each dimension separately. For example, a medication
could result in an average improvement of 10% on symptom measures and also result in
5% increase in side effects. However, it is difficult to determine if the same patients are
experiencing both symptom improvement and side effects or if one subpopulation is
experiencing the majority of clinical benefit and another population is experiencing
predominant increase in side effects. In our analysis, the health states encompass both
symptoms and side effects so we can easily assess the overall impact of treatment over
time.

In this analysis, we showed that at baseline, the majority of patients were in
health states with a high symptom and side effect burden (39% in HS+LSE and 20% in
HS +Dp+Ak). However, there was also a significant proportion of patients at baseline in
the LS+LSE health state. Over 6 months of treatment, averaging transitions across all
study medications, there was a large increase in the LS+ LSE health state and a large
decrease in the HS+LSE and HS+Dp+Ak indicating that in general, the same patients
who experienced a decrease in symptoms also experienced a decrease in side effects.
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However, there was also a sizable increase in the proportion of patients in the low
symptoms and high obesity (BMI) health state (5% increase) in the course of 6 months.
And at 6 months, over a third of patients still experienced moderate to high levels of
symptoms and side effects. Interestingly, the proportion of patients in the MS+HSE state
remained relatively low and constant over the 6 months (3.5% increase to 5.8% at 6
months). This health state may have represented a small group of patients who were
treatment resistant or were predisposed to experience a high level of side effects.

The final aim of this study was to determine whether there were differences in the
distribution of changes in health states across different medications. Despite a group of
very large meta analyses indicating that only a few SGA’s potentially provide better
outcomes and several large multi-site national trials indicating that SGA’s do not provide
better outcomes over the FGA’s used in those trials, there is still considerable controversy
about the relative effectiveness of the newer SGA medications. In addition, many
clinicians still believe SGA’s are more efficacious in general, although those opinions are
likely based as much on intensive marketing as on knowledge of outcomes research
results (24). Thus, there is a need for additional comparative effectiveness research that
could provide evidence to further guide clinicians in their choice of treatments.

In our intent to treat analysis, we showed that the distribution of patients across
clusters at 6 months was significantly different across the four medications (p = 0.009).
After comparing each pair of medications amongst the four, we find that the health state
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distributions were significantly different only between perphenazine and risperidone (p =
0.012 < α of 0.025 after Hochberg correction) and between olanzapine and risperidone (p
= 0.001 < α of 0.05 after Hochberg correction). Comparing the percentage of patients in
the five clusters at 6 months, it was clear that both perphenazine and olanzapine resulted
in a larger increase in the LS+LSE (best) health state and a larger decrease in the
HS+Dp+Ak (worst) health state in comparison to risperidone. Risperidone was also
associated with the smallest decrease in the HS+LSE health. Risperidone resulted in
similar changes in the LS+Ob and MS+HSE health states so that overall, it appeared that
perphenazine and olanzapine were significantly superior medications to risperidone, at
least at the dosages used in this double blind trial. There were no significant differences
between any other pair of medications.

Compared to recent large meta analyses, our results align most closely with that
of Geddes and colleagues (14) who found that SGA’s as a group were no more effective
than FGA’s. However, in contrast to our analysis, they also found that SGA’s show a
moderate benefit in EPS symptoms. The reviews by both Davis and colleagues (15)and
Leucht and colleagues(16) both concluded that olanzapine and risperidone were
significantly more effective than FGA’s and were also associated with fewer EPS,
although the Leucht review noted that the evidence was predominantly based on
comparisons with the high potency drug haloperidol, and were far less clear for
comparisons with low or intermediate potency FGA’s. The use of perphenazine, an
intermediate potency antipsychotic, may account for some of the differences in findings.

36

In our analysis, perphenazine was associated with a similar decrease in HS+Dp+Ak and
MS+HSE, the two health states with high movement side effects, compared with the
three SGA’s in this study. In addition, as acknowledged by Leucht and colleagues, the
effectiveness design of the CATIE and CUtLASS studies was quite different from the
efficacy designs used by most of the studies included in the meta analyses, and thus more
informative about real-world practice (16). Most previous studies, like many of those
used in the meta analyses addressed safety and efficacy whereas the two large scale
clinical trials focused more on real world effectiveness by including diverse sites and
allowing far broader inclusion and fewer exclusion criteria.

Unsurprisingly, our results are closely aligned with those of the original CATIE
analysis. The primary results indicated that olanzapine was associated with a longer time
to discontinuation compared to risperidone and quetiapine, but not compared to
perphenazine (31). There were no significant differences between any SGA and
perphenazine on measures of symptoms, side effects, or quality of life. Although the
results indicated similar conclusions overall, there are some differences. For example,
our results showed that perphenazine and olanzapine were associated with a significantly
different distribution of health states compared to risperidone. Risperidone was
associated with the smallest changes in LS+LSE, HS+Ak+Dp, and HS+LSE. These
changes suggested that risperidone was associated with the lowest probability of
transitioning a patient to an improved health state. This data could potentially provide
more concrete guidance for clinicians in their choice of treatment. Although risperidone
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may be associated with some improvements as seen on average changes on various
outcomes measures, our results suggested that the medication was associated with the
lowest probability of significant clinical improvement as defined by the health states in
this study.

An additional goal of this study was that health state analysis could be used to
obtain long run predictions on the distribution of patients across health states under the
different medications. In order to obtain these predictions, we tested the data for the
assumptions of Markov chain theory which requires that the data fit both the stationary
criteria, where the transition probabilities from one state to another would remain fixed
over time, and also the assumption that the transition probabilities could depend on
nothing other than the previous health state. However, since our data did not appear to
meet these criteria, Markov analysis could not be conducted. Specifically when
evaluating data across the entire 18 month study period, it appeared that transition
probabilities were dependent on more than just the previous health state. We surmise that
this finding is likely to reflect the high dropout rate over the course of 18 months during
the CATIE trial. In fact, over 74% of the patients discontinued their initial study
medication prior to the end of the trial. In order to test the impact of dropout on the
results of our first 6 month analysis, we evaluated the sample for differences in clinical
and demographic features between those who stopped their study medication at 6 months
and those who stayed and found no significant differences in between the two groups.
However, it was still possible that the pattern of patients dropping out changes over the
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course of the 18 months and lended significant variability to the pattern of transition
probability over time. Thus, in this analysis we focused only on changes in health state
over the first 6 months, a clinically meaningful interval, during which drop outs were
limited.

The health state approach as applied to the CATIE data has several limitations.
First, the generation of clusters was completely data driven and was based on the data for
the sample at hand. As a result, the observed clusters may not be generalizable to other
clinical samples. We used data from a large clinical trial designed to assess differences in
effectiveness of medications under real world conditions. Although the study had broad
inclusion and exclusion criteria, the sample may still represent a subset of patients with
chronic schizophrenia who may have failed previous treatments. A second limitation was
the challenge of applying statistical tests to the cluster distributions we obtained.
Although we use chi square test to determine if the distribution of health states is the
same for patients receiving different treatments, we must also analyze the percent of
patients within the different health states to determine if one pattern of health states is
preferable to another. In addition, the health states themselves may not pick up on subtle
differences in outcome. For example, our results showed that the changes in proportion
of patients in LS+Ob was similar for patients treated with perphenazine, olanzapine and
risperidone, but was higher for those in the quetiapine group. However, we also found
that the difference in BMI from baseline to 6 months was highest for olanzapine and was
significantly higher than perphenazine (p<0.01). These results combined with the
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original CATIE trial results showing a greater increase in BMI for patients treated with
olanzapine, suggest that there can be heterogeneity within a cluster that may mask some
significant differences in outcome across treatment groups.

This example also illustrates the challenge of directly comparing health state
analysis with outcomes of traditional dimensional methods. Because health state analysis
clusters patients along various dimensions of health, it can be challenging to compare the
results to traditional methods that compare patients along single dimensions of health.
Finally, with health state analysis, there is an element of judgment in determining the
appropriate number of health states that balances detail against simplicity. In this
analysis, the final selection of number of health states was strongly influenced by need
for ease of interpretability and parsimony.

Conclusion

In this study, we show that health state analysis is a useful tool in the comparison
of multiple treatments for a clinically complex illness such as schizophrenia. It not only
strengthens previous results, but can also provide additional insights into the differences
in overall health outcomes of patients. From our analysis, we conclude that SGA’s are
not a homogenous group in terms of effectiveness. And as a group, they are no more
superior to perphenazine, an intermediate potency FGA, which is associated with a large
proportion of patients with improved symptom and side effect profiles. These results are
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now added to a growing body of work indicating that SGA’s as a group are not better
than many FGA’s on symptoms and side effects taken as a whole. The release of many
new SGA’s in the last decade with strikingly similar mechanisms, symptom and side
effect profiles may make it more challenging for clinicians to decide on the most
appropriate treatment for patients. However, with the nation’s rapidly rising healthcare
costs, it is imperative that clinicians look to well substantiated evidence based treatments.
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Appendix 1

Clinical and demographic characteristics across medications of sample used for initial
clustering*.

Age
Male
Race/Ethnicity
White
Black
Hispanic
Marital Status
Married
Separated/
Divorced
Never
Married
PANSS Total
Positive
Negative
General

Total Sample
Olanzapine
Perphenazine
Quetiapine
Risperidone
Mean/N %/SD Mean/N %/SD Mean/N %/SD Mean/N %/SD Mean/N %/SD
N=1049
N=263
N=256
N=261
N=269
39.3
10.9 39.36
10.56 39.97 11.06
39.15
10.88
38.78 11.05
777 74.0%
190
72.2%
196 76.6%
192 73.5%
199 74.0%
631
368
129

60.1%
35.1%
12.3%

153
96
37

58.2%
36.5%
14.1%

151 59.0%
90 35.1%
24 9.3%

167
84
39

64.0%
32.1%
14.9%

160
98
29

59.5%
36.4%
10.8%

131

12.5%

30

11.4%

43 16.8%

27

10.3%

31

11.5%

219

20.8%

61

23.2%

50 19.4%

55

20.9%

53

19.8%

636
75.5
18.4
20.2
36.9

60.6%
17.5
5.6
6.5
9.3

159
75.7
18.4
20.3
37.0

60.4%
18.2
5.5
6.7
9.8

146 57.0%
74.2
18.0
17.9
5.9
20.3
6.3
36.0
9.5

167
74.8
18.3
19.8
36.7

64.0%
17.0
5.4
6.5
9.2

164
77.2
19.0
20.4
37.8

61.0%
16.5
5.6
6.4
8.6

Depression
1.6
0.6
1.6
Side Effects
Simpson
Angus
0.18
0.29
0.16
Barnes
0.47
0.84
0.58
AIMS
0.12
0.27
0.15
BMI
29.80
7.09 29.24
Health costs (previous month)
All
medication
$422
$325 $419
Inpatient/
Residential $1,512 $3,715 $1,828
Outpatient
$365
$935 $379
Total
$2,299 $3,831 $2,628

0.6

1.6

0.6

1.6

0.6

1.6

0.6

0.27
0.97
0.31
6.86

0.19
0.43
0.12
29.63

0.32
0.79
0.27
6.93

0.16
0.46
0.11
30.22

0.25
0.76
0.24
7.05

0.20
0.47
0.12
30.09

0.29
0.81
0.23
7.48

$344

$420

$314

$418

$331

$433

$313

$3,988 $1,127 $2,530
$864
$392 $1,173
$4,078 $1,940 $2,811

$1,442
$410
$2,271

$3,642
$1,066
$3,813

* Data courtesy of Supplemental Table 1 of (42)

$1,636 $4,381
$281
$513
$2,352 $4,389

